Clearing FDA. When the Food and Drug Administration places an administrative hold on a medical device shipment at the Port of Los Angeles (POLA), demurrage and detention fees begin accruing immediately. Marine terminals at POLA and neighboring Long Beach enforce strict free-time windows, leaving importers very little time to resolve document mismatches or physical examination requests before container storage costs escalate into thousands of dollars.
Resolving these holds requires a systematic approach: identifying the specific mechanism stalling your entry, matching your technical documentation to FDA records, and submitting targeted data packets directly through the proper electronic channels.
Understanding FDA Hold Classifications at POLA
Medical device entries transmitted through the Automated Commercial Environment (ACE) encounter two primary types of regulatory holds:
- FDA Examination or Review Hold: The status reflects that “FDA MAY PROCEED” has been withheld. This typically indicates an automated data flag or a manual desk review conducted by compliance officers at the FDA’s Los Angeles District import operations office.
- Notice of FDA Action (Detention and Hearing): This is a formal administrative action issued under Section 801(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The notice specifies that the device appears to be adulterated, misbranded, or manufactured in an unregistered facility, triggering a strict response window (typically 10 to 20 business days) before FDA issues a Notice of Refusal of Admission.
Audit Affirmation of Compliance (AOC) Codes
The vast majority of desk-review holds at POLA stem from inaccurate or incomplete Affirmation of Compliance (AOC) codes submitted by customs brokers during initial entry filing. An entry flag occurs whenever ACE transmission data does not match records in the FDA Unified Registration and Listing System (FURLS).
Importers must cross-reference their entry paperwork against four critical identifiers:
- Premarket Submission Number (PMN): Verify that the 510(k), PMA, or De Novo clearance number matches the cleared indications for the device. If the device is 510(k)-exempt, confirm that the broker transmitted the correct exempt product code rather than leaving the field blank.
- Device Listing Number (LST): Ensure the 7-digit listing number corresponds directly to the active commercial distribution record in FURLS.
- Foreign Manufacturer Registration (DEV): Check that the foreign establishment’s registration number (FEI) is active and that annual registration user fees (MDUFA) are fully paid for the current fiscal year.
- Device Initial Importer (DII): Confirm that the U.S. entity listed as the importer of record on CBP Form 7501 holds an active Initial Importer registration with the FDA.
When an AOC error is identified, your customs broker must submit an electronic entry correction in ACE or upload revised commercial invoices and device specifications directly via FDA’s Import Prior Notice and Entry Review portal (ITACS).
Managing Physical Examinations and Wharf Inspections
If the FDA issues a physical exam hold, the container cannot move into domestic commerce until FDA consumer safety officers complete a physical check. At POLA, cargo may be inspected directly at the marine terminal or transferred under customs bond to a Centralized Examination Station (CES) like Price Transfer or FCL Logistics.
Physical examinations focus on device labeling compliance under 21 CFR Part 801 and Unique Device Identification (UDI) requirements under 21 CFR Part 830:
- Labeling Integrity: Outer packaging, unit cartons, and package inserts must display the manufacturer’s name, place of business, adequate directions for use, and required prescription statements (e.g., “Rx only” if applicable).
- UDI Rules: Devices must bear a proper UDI label in both human-readable plain text and automatic identification and data capture (AIDC) format, matched against records in the Global Unique Device Identification Database (GUDID).
If labeling defects are discovered during an inspection, importers can prevent outright refusal by submitting Form FDA-766 (Application for Authorization to Relabel and to Perform Other Action). This formally requests authorization to bring the non-compliant goods into legal compliance under FDA supervision at a designated bonded warehouse.
Assembling a Detention Rebuttal Package
Receiving a formal Notice of FDA Action requires a structured legal and technical response submitted directly to the assigned compliance officer before the hearing date expires.
Your response submission should contain:
- High-resolution photographs of production labels, showing the exact placement of UDI identifiers, lot numbers, and distributor/manufacturer markings.
- Copy of the FDA 510(k) clearance letter or PMA approval order tying the trade name directly to the specific model numbers in the container.
- Device Master Record (DMR) excerpts establishing manufacturing specifications and quality system compliance (21 CFR Part 820).
- Proof of valid foreign site registration and active listing status pulled directly from the public FDA database.
Once the compliance officer reviews and accepts the evidence, an updated Notice of FDA Action showing “MAY PROCEED” will be issued. This release automatically updates CBP systems, lifting the customs hold and allowing final drayage to proceed.
FAQ
What is the difference between a CBP hold and an FDA hold on medical devices?
A CBP hold relates to tariff classification, customs valuation, intellectual property, or general security checks. An FDA hold is a Partner Government Agency (PGA) action based strictly on regulatory compliance under the FD&C Act, such as registration, listing, labeling, or premarket clearance.
Can I move my container out of the Port of Los Angeles while under an FDA review hold?
Importers may request permission to move containers under a CBP conditional release bond to an off-port bonded warehouse or secure facility within the port limits while awaiting FDA admissibility decisions, preventing severe terminal demurrage charges.
What happens if an FDA medical device hold is ignored?
If you fail to respond to a Notice of FDA Action before the specified deadline, the FDA will issue a Notice of Refusal of Admission. Once refused, the merchandise must be exported or destroyed under CBP and FDA supervision within 90 days.
How long does the Los Angeles FDA District office take to review submitted entry documentation?
Electronic documents submitted through ITACS are typically processed within 2 to 5 business days, though complex inquiries involving laboratory testing, physical wharf exams, or formal detentions may take 1 to 3 weeks depending on port volume.
Can a foreign manufacturer contact the FDA directly to resolve an import hold?
While foreign manufacturers can provide technical documentation, communications regarding import holds are generally coordinated through the U.S. Designated Agent, the Initial Importer of record, or the licensed customs broker managing the ACE entry.
Book a Free Consultation Call if your medical device shipment is held at the Port of Los Angeles. We audit your ACE entry data, correct AOC mismatches, draft formal detention rebuttals, and secure your FDA release before port storage costs escalate.
